Century Therapeutics, Inc. (NasdaqCM: IPSC)
Health Care · Biotechnology · US
$2.12
+2.42% today · +304.9% 1Y
Century Therapeutics, Inc. (NasdaqCM: IPSC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $374.83M and employs 78 people.
Over the last twelve months the share price has gained 304.9%, trading between 0.44 and 3.04.
Tweenvest scores Century Therapeutics, Inc. across four factors: quality 37/100. Its strongest factor is quality.
IPSC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $374.83M
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -0.77
- Dividend yield
- —
- Beta (5Y)
- 1.60
- 52-week high
- $3.04
- 52-week low
- $0.44
- Avg volume (3M)
- —
- Shares outstanding
- 181.08M
- Employees
- 78
- Next earnings
- —
About Century Therapeutics, Inc.
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
- ISIN
- US15673T1007
- Founded
- 2018
- Listed since
- Jun 18, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.